A new meta-analysis looked at whether hydroxychloroquine, a common lupus medication, helps prevent pregnancy complications in women with systemic lupus erythematosus (SLE). The analysis combined data from several studies, including over 1,100 pregnant women for the pre-eclampsia outcome.
The results were mixed. Hydroxychloroquine use was not linked to a lower risk of pre-eclampsia, miscarriage, hypertensive disorders, or preterm delivery. However, it was associated with a significantly lower risk of fetal growth restriction (about 59% lower odds) and gestational diabetes (about 72% lower odds).
It is important to note that this was a meta-analysis of observational studies and some randomized trials, so the findings show associations, not proof of cause and effect. The authors also noted that the results differ from some earlier individual studies. The main limitation was that the original studies did not account for whether women had been pregnant before, which could affect outcomes.
For now, the evidence suggests hydroxychloroquine may offer some benefits for certain pregnancy outcomes in lupus, but more high-quality research is needed. Women with lupus who are pregnant or planning pregnancy should discuss their medications with their rheumatologist and obstetrician.
